Boston Scientific CRT lead
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific announces May 16 FDA market go-ahead for its Acuity Spiral left ventricular lead for cardiac resynchronization devices, such as its Cognis cardiac resynchronization therapy defibrillator (CRT-D) approved May 13 (1"The Gray Sheet" May 19, 2008, In Brief). Acuity Spiral has a spiral fixation design and small lead tip, tapering from size 4.1 French to 2.6 French. The company is sponsoring a five-year, 1,700-patient, 125-center registry to study the real-world performance of Acuity Spiral with the Latitude remote monitoring system. Acuity Spiral earned a CE mark in March (2"The Gray Sheet" March 10, 2008, p. 12)
You may also be interested in...
Boston Scientific Cognis and Teligen
Firm announces FDA approval May 13 for its next-generation high-voltage cardiac rhythm management platform devices - the Cognis cardiac resynchronization therapy defibrillator (CRT-D) and Teligen implantable caridoverter defibrillator (ICD). The devices "are among the world's smallest and thinnest high-energy devices" at 32.5 cc and 31.5 cc in volume, respectively, and under 10 mm thick, the firm states. Key Cognis features include SmartDelay to quickly propose programmable device settings and Electronic Repositioning with six different options for stimulating the left side of the heart. Teligen features include Quick Convert for pacing treatment of ventricular tachycardias and Enhanced AV Search to minimize unnecessary right ventricular pacing. Both devices also provide extended battery longevity over previous Boston Scientific offerings
New Products In Brief
Spiral lead CE mark: Boston Scientific will market its Acuity Spiral left ventricular lead by mid-March outside the United States for use with cardiac resynchronization therapy devices to treat heart failure. The product boasts a 4-French lead tip profile, the smallest tip in the industry, the firm says. Boston Scientific anticipates U.S. approval of the lead by July
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.